Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS. Armstrong AW, et al. Among authors: menter ma. J Am Acad Dermatol. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28. J Am Acad Dermatol. 2017. PMID: 27908543 Free article. Review.
Treating to Target-A Realistic Goal in Psoriasis?
Gordon KB, Armstrong AW, Menter MA, Wu JJ. Gordon KB, et al. Among authors: menter ma. Semin Cutan Med Surg. 2018 Feb;37(2S):S44-S47. doi: 10.12788/j.sder.2018.010. Semin Cutan Med Surg. 2018. PMID: 29614137 Review.
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter MA. Lebwohl MG, et al. Among authors: menter ma. J Am Acad Dermatol. 2021 Feb;84(2):398-407. doi: 10.1016/j.jaad.2020.09.047. Epub 2020 Sep 19. J Am Acad Dermatol. 2021. PMID: 32961255 Free article. Clinical Trial.
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS; Tazarotene Cream Clinical Study Group. Weinstein GD, et al. Among authors: menter ma. J Am Acad Dermatol. 2003 May;48(5):760-7. doi: 10.1067/mjd.2003.103. J Am Acad Dermatol. 2003. PMID: 12734506 Clinical Trial.
The Evolving Landscape of Psoriasis Treatment.
Armstrong AW, Gordon KB, Menter MA, Wu JJ. Armstrong AW, et al. Among authors: menter ma. Semin Cutan Med Surg. 2018 Feb;37(2S):S39-S43. doi: 10.12788/j.sder.2018.009. Semin Cutan Med Surg. 2018. PMID: 29614136 Review.
Common and Not-So-Common Comorbidities of Psoriasis.
Menter MA, Armstrong AW, Gordon KB, Wu JJ. Menter MA, et al. Semin Cutan Med Surg. 2018 Feb;37(2S):S48-S51. doi: 10.12788/j.sder.2018.011. Semin Cutan Med Surg. 2018. PMID: 29614138 Review.
Practical Strategies for Optimizing Management of Psoriasis.
Wu JJ, Armstrong AW, Gordon KB, Menter MA. Wu JJ, et al. Among authors: menter ma. Semin Cutan Med Surg. 2018 Feb;37(2S):S52-S55. doi: 10.12788/j.sder.2018.012. Semin Cutan Med Surg. 2018. PMID: 29614139 Review.
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Thaçi D, et al. Among authors: menter ma. Dermatol Ther (Heidelb). 2022 Feb;12(2):495-510. doi: 10.1007/s13555-021-00649-y. Epub 2022 Jan 13. Dermatol Ther (Heidelb). 2022. PMID: 35025062 Free PMC article.
65 results